EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database

Sakura Hiraide Taniguchi, Masanobu Takahashi, Shih-Wei Chiu, Keigo Komine, Shonosuke Wakayama, Ryunosuke Numakura, Yuya Yoshida, Yuki Kasahara, Kota Ouchi, Hiroo Imai, Ken Saijo, Hidekazu Shirota und 1 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-025-02724-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Sakura Hiraide Taniguchi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan. Hauptthemen laut MEDLINE: Appendiceal Neoplasms, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Appendiceal carcinoma (AC) is a rare malignancy and has distinct genomic features, but their impact on prognosis and chemotherapy efficacy requires further investigation.

Methods

This retrospective study analyzed patients with advanced AC from the Japanese nationwide comprehensive genomic profiling test database, the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, focusing on genetic alterations and their associations with clinical outcomes.

Results

Of the 314 patients, the histological types Queryincluded adenocarcinoma (Ad) (51.9%), mucinous adenocarcinoma (MAd) (30.3%), goblet cell adenocarcinoma (12.4%), and signet-ring cell adenocarcinoma (5.4%). The most common mutations were KRAS (52.5%), TP53 (49.4%), SMAD4 (18.8%), and GNAS (17.2%). KRAS mutations were most frequent in MAd (68.4%) and Ad (58.9%), whereas TP53 mutations were mostly prevalent in Ad (62.6%). We classified patients into molecular subtypes based on the presence of mutations and analyzed differences in overall survival (OS) by molecular subtype. Patients with TP53 -mutant (mut) dominant tumors (all TP53 -mut) and KRAS -mut focused tumors ( TP53 -wild-type (wt)/ GNAS -wt/ KRAS -mut/any SMAD4 ) showed a poorer median OS compared with those with GNAS -mut focused tumors ( TP53 -wt/ GNAS -mut/any KRAS /any SMAD4 ) (median 47.4 and 37.5 months vs. not reached; p = 0.01 and p = 0.01, respectively). TP53 mutation was associated with poor time to treatment failure and OS with the oxaliplatin-based regimen for first-line chemotherapy.

Conclusions

This study suggested that the genetic mutations influenced the prognosis and chemotherapy efficacy in AC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Appendiceal NeoplasmsMutationHumansFemaleMaleMiddle AgedAgedPrognosisSmad4 ProteinRetrospective StudiesAdultTumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)JapanAged, 80 and overChromograninsGTP-Binding Protein alpha Subunits, GsDatabases, GeneticGenomicsEast Asian People

Stichwörter der Autor:innen

Appendiceal carcinomaComprehensive genomic profiling testGenomePrognosisSystemic chemotherapy

Substanzen

Smad4 ProteinSMAD4 protein, humanTumor Suppressor Protein p53KRAS protein, humanProto-Oncogene Proteins p21(ras)GNAS protein, humanTP53 protein, humanChromograninsGTP-Binding Protein alpha Subunits, Gs

Autor:innen und Institutionen

  • Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
  • Department of Clinical Oncology, Tohoku University Graduate School of Medicine, 4-1, Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan.
  • Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan. masanobu.takahashi.a7@tohoku.ac.jp.
  • Department of Clinical Oncology, Tohoku University Graduate School of Medicine, 4-1, Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan. masanobu.takahashi.a7@tohoku.ac.jp.
  • Clinical Research Data Center, Tohoku University Hospital, Sendai, Japan.

Zitieren

APA

Taniguchi, S. H., Takahashi, M., Chiu, S. W., Komine, K., Wakayama, S., Numakura, R., Yoshida, Y., Kasahara, Y., Ouchi, K., Imai, H., Saijo, K., Shirota, H., & Ishioka, C. (2025). Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02724-2

Vancouver

Taniguchi SH, Takahashi M, Chiu SW, Komine K, Wakayama S, Numakura R, et al. Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02724-2

BibTeX
@article{Taniguchi2025,
  author = {Taniguchi, Sakura Hiraide and Takahashi, Masanobu and Chiu, Shih-Wei and Komine, Keigo and Wakayama, Shonosuke and Numakura, Ryunosuke and Yoshida, Yuya and Kasahara, Yuki and Ouchi, Kota and Imai, Hiroo and Saijo, Ken and Shirota, Hidekazu and Ishioka, Chikashi},
  title = {Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test database},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-025-02724-2}
}
Kostenlos starten →